In the relentless pursuit of enhanced cancer treatments, recent research has shed light on the dual inhibition of MYCN and MDM2 as a promising strategy. Both MYCN and MDM2 are vital oncogenes implicated in various tumorigenic processes. Their simultaneous targeting might revolutionize the
New research shines light on position-specific hallmarks of cancer, diving deeply into the contemporary understanding of cancer and focusing on the specific expression patterns of cancer hallmarks within tumors. The fundamental question it addresses is, "What is a tumor?"—a crucial query when
Prostate cancer screening has long relied on blood tests, MRIs, and biopsies, each carrying its own set of drawbacks, such as causing discomfort and leading to the overdiagnosis of low-grade cancers that might not pose significant health risks. These traditional approaches, while effective in
The groundbreaking research conducted by Van Andel Institute scientists sheds new light on how developmental epigenetic changes can profoundly influence cancer risk later in life. The study, published in Nature Cancer, identifies two distinct epigenetic states formed during development, which are
The NHS BRCA Testing Program launched in January 2023 has been a significant success in England, offering free genetic testing to individuals with Jewish ancestry to identify their risk of inherited cancers. This initiative targets people aged 18 or over with at least one Jewish grandparent, and it
In York, a family's journey of resilience and gratitude has culminated in a remarkable fundraising achievement for Cancer Research UK. The Burn family, inspired by their mother's successful battle against cancer, transformed their personal trials into a community-driven mission to support the
